Truist analyst Richard Newitter lowered the firm's price target on SI-Bone to $18 from $20 and keeps a Buy rating on the shares. The firm notes that its reduced price target reflects a lower multiple as the company's peer group has experienced multiple compression, though it is also positive on the company's good Q1 results with solid gross margins and EBITDA beat, the analyst tells investors in a research note.
